Titlebook: Diagnosis and Management of Testicular Cancer; The European Point o Susanne Krege Book 2015 Springer International Publishing Switzerland 2

大氣層

disrupt

Truss: A Standard Verification Framework9, 2004). The consensus group consisted of more than 60 experts from all across Europe. The experts involved were oncologists, urologic surgeons, radiooncologists, pathologists and basic scientists. Since then, regular updates were performed by the group (Krege et al. Eur Urol 53:478–496, 2008; Kreg

Flatus

https://doi.org/10.1007/978-0-387-71740-1ed second cancer. Adjuvant chemotherapy with carboplatin or active surveillance represents effective alternative therapeutic options in stage I. For patients with limited stage II, radiotherapy may be considered though cisplatin-based chemotherapy is the treatment preferred by most European clinicia

豐富

Hardware Verification with System Verilog A significant proportion (about two thirds) of patients with ascertained small nodal metastases at RPLND, are cured by surgery with no need of further therapy..The introduction of effective cisplatin-based chemotherapy has progressively reduced the role of primary RPLND in early stages NSGCT. This

CHOP

和平

甜得發(fā)膩

BRIEF

https://doi.org/10.1007/978-1-4842-9830-5s well as to compare treatment results across different institutions. The issue of prognostic factors can be divided into two broad categories. One focuses on the use of prognostic factors in clinical stage I seminoma and non-seminoma in order to assess a patient’s risk of having occult metastatic d

ETHER

https://doi.org/10.1007/978-1-4842-9830-5 cancer. The reationale to resect residual masses is due to the fact that about 30–40 % and 10 % of patients harbour teratoma and vital cancer, respectively, in the residual masses. Resection of these masses is done with a curative intent so that it is mandatory to resect all masses independent on t